Skip to main content

Table 2 Univariable cox regression analysis of clinical factors potentially associated with overall survival (OS) and progression free survival (PFS)

From: Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer

 

OS

PFS

 

Univariable HR (95 % CI)

p

Univariable HR (95 % CI)

p

Age, years

    

 >60 vs. S 60

1.25 (0,70-2,23)

0.44

1.10 (0,65-1,85)

0.72

Sex

    

 Female vs. male

1.19 0.66-2.13)

0.57

1.00 (0.59-1.69)

0.99

KPS

    

 90 % vs. 70–80%

0.68 (0.37-1.24)

0.21

0.51 (0.29-0.89)

0.018

Weight loss

    

 S 5 % vs. > 5 %

0.78 (0.31-1.99)

0.60

1.18 (0.53-2.63)

0.69

M1-stage - time of occurence

    

 Metachronous vs. synchronous

1.26 (0.71-2.24)

0.43

1.46 (0.87-2.48)

0.15

Histology

    

 Squamous vs.Adeno.

0.64 (0.28-1.46)

0.29

0.75 (0.37-1.50)

0.42

T -Stagea

    

 T3/T4 vs. T1/T2

0.79 (0.41-1.52)

0.29

1.02 (0.59-1.79)

0.94

N-Stagea

    

 N2/N3 vs.N0/N1

1.27 (0.71-2.25)

0.43

1.26 (0.74-2.15)

0.40

Thoracic UICC stage

    

 II vs. I

2.28 (0.87-5.96)

0.09

3.80 (1.36-10.69)

0.011

 III vs. I/II

0.85 (0.48-1.51)

0.59

0.84 (0.49-1.43)

0.53

Localization of metastases

    

 Other vs. Brain

0.80 (0.43-1.51)

0.50

0.48 (0.26-0.91)

0.024

No. of metastases

    

 > 2 vs. 1

1.10 (0.56-2.17)

0.79

1.26 (0.71-2.26)

0.43

No. of involved organs

    

 > 2 vs. 1

1.03 (0.32-3.33)

0.96

2.90 (1.30-6.46)

0.009

T reatment of primary tumor

    

 Without vs. with Surgery

1.58 (0.74-3.40)

0.24

1.07 (0.58-1.96)

0.84

T reatment of oligometastases

    

 SRS/hSRT/SBRT vs. Surgery

1.00 (0.36-2.84)

0.99

0.75 (0.29-1.95)

0.55

FDG-PET based staging

    

 PET vs. no PET

1.00 (0.54-1.84)

1.00

0.84 (0.48-1.47)

0.54

Additional chemotherapy

    

 CT vs. no CT

0.69 (0.39-1.23)

0.21

0.84 (0.49-1.44)

0.52

  1. SD standard deviation, RT radiotherapy, CT chemotherapy, RCT radiochemotherapy, SBRT stereotactic body radiotherapy, SRS stereotactic radiosurgery, hSRT hypofractionated stereotactic radiosurgery, cf-RT conventionally fractionated radiotherapy, KPS Karnofsky Performance Score
  2. arefers to initial staging also for patients with metachronous metastases